Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

被引：0
|
作者：
Patel, Shruti R. [1 ,2 ]
Neal, Joel W.
机构：
[1] Stanford Univ, Stanford Canc Inst, Dept Med, Div Med Oncol, Palo Alto, CA USA
[2] Stanford Univ, Stanford Canc Inst, Dept Med Oncol, Palo Alto, CA 94305 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 07期
关键词：
Osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); adjuvant; ADAURA;
D O I：
10.21037/tlcr-23-273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1631 / 1635
页数：5
相关论文
共 50 条
  • [1] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [2] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
  • [3] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [4] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [6] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [7] Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report
    Lasvergnas, Julie
    Monnet, Isabelle
    Auliac, Jean-Bernard
    Rousseau-Bussac, Gaelle
    Chouaid, Christos
    Assie, Jean-Baptiste
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 287 - 291
  • [8] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [9] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [10] Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China
    Zhou, Xiwen
    Du, Jianting
    Xu, Guobing
    Chen, Chun
    Zheng, Bin
    Chen, Jiahe
    CANCER MEDICINE, 2022, 11 (23): : 4449 - 4456
12345